EP0752880A4 - TREATMENT OF AUTOIMMUNE DISEASES USING ORAL TOLERANCE AND / OR INTERFERON TYPE I - Google Patents

TREATMENT OF AUTOIMMUNE DISEASES USING ORAL TOLERANCE AND / OR INTERFERON TYPE I

Info

Publication number
EP0752880A4
EP0752880A4 EP95916183A EP95916183A EP0752880A4 EP 0752880 A4 EP0752880 A4 EP 0752880A4 EP 95916183 A EP95916183 A EP 95916183A EP 95916183 A EP95916183 A EP 95916183A EP 0752880 A4 EP0752880 A4 EP 0752880A4
Authority
EP
European Patent Office
Prior art keywords
treatment
autoimmune diseases
oral tolerance
interferon type
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916183A
Other languages
German (de)
French (fr)
Other versions
EP0752880A1 (en
Inventor
David A Hafler
Howard L Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP0752880A1 publication Critical patent/EP0752880A1/en
Publication of EP0752880A4 publication Critical patent/EP0752880A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
EP95916183A 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASES USING ORAL TOLERANCE AND / OR INTERFERON TYPE I Withdrawn EP0752880A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US225372 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
EP0752880A1 EP0752880A1 (en) 1997-01-15
EP0752880A4 true EP0752880A4 (en) 2000-08-09

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916183A Withdrawn EP0752880A4 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASES USING ORAL TOLERANCE AND / OR INTERFERON TYPE I

Country Status (9)

Country Link
EP (1) EP0752880A4 (en)
JP (1) JPH09511745A (en)
AU (1) AU686797B2 (en)
BR (1) BR9507451A (en)
CA (1) CA2185353A1 (en)
HU (1) HUT74900A (en)
IL (1) IL113303A0 (en)
NO (1) NO964199L (en)
WO (1) WO1995027499A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
KR101042660B1 (en) * 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 Stable Liquid Interferon Formulations
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU6481301A (en) 2000-05-24 2001-12-03 Us Health Methods for preventing strokes by inducing tolerance to e-selectin
WO2004058295A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Remedy for pemphigoid
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
AU2010234743A1 (en) * 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (en) * 2013-11-11 2019-10-16 キッコーマン株式会社 Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (en) * 1988-01-22 1989-07-26 Collagen Corporation Method for suppressing the growth of normal and cancer cells
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (en) * 1988-01-22 1989-07-26 Collagen Corporation Method for suppressing the growth of normal and cancer cells
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9527499A1 *

Also Published As

Publication number Publication date
HU9602750D0 (en) 1996-11-28
EP0752880A1 (en) 1997-01-15
HUT74900A (en) 1997-02-28
NO964199D0 (en) 1996-10-03
AU2277695A (en) 1995-10-30
NO964199L (en) 1996-10-03
WO1995027499A1 (en) 1995-10-19
JPH09511745A (en) 1997-11-25
CA2185353A1 (en) 1995-10-19
AU686797B2 (en) 1998-02-12
IL113303A0 (en) 1995-07-31
BR9507451A (en) 1997-08-05

Similar Documents

Publication Publication Date Title
EP0773716A4 (en) TREATMENT OF RED CELL SOLUTIONS WITH ANTIVIRAL AGENTS
EP0754042A4 (en) TREATMENT OF ATHEROSCLEROSIS
EP0831836A4 (en) SYNTHETIC FREE RADICAL CATALYTIC INTERCEPTORS FOR USE AS ANTIOXIDANTS IN THE PREVENTION AND TREATMENT OF DISEASES
EP0979074A4 (en) TREATMENT OR PREVENTION OF MENOPAUSIC SYMPTOMS AND OSTEOPOROSIS
EP0921819A4 (en) TREATMENT AND PREVENTION OF CANCERS BY ADMINISTRATION OF HUMAN CHORIONIC GONADOTROPHIN DERIVATIVES
FI973163L (en) Treatment of incontinence using (S)-oxybutynin and (S)-desethyloxybutynin
EP0925046A4 (en) TOPICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF HEMORROIDAL PAIN
EP0752880A4 (en) TREATMENT OF AUTOIMMUNE DISEASES USING ORAL TOLERANCE AND / OR INTERFERON TYPE I
FI973468L (en) Method for manufacturing preparations for use in teeth whitening or in the treatment of skin and mucous membrane diseases
EP0954300A4 (en) PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION
BR9305310A (en) Cam set and "S" cam set
EP0861082A4 (en) TREATMENT OF INSUFFICIENCY OF THE TISSUE MEMBRANE
EP0832204A4 (en) TREATMENT OF INSULIN RESISTANCE
EP0506893A4 (en) Diagnosis and treatment of diseases
EP0959879A4 (en) PHOTODYNAMIC THERAPY FOR THE TREATMENT OF ARTHROSIS
EP1011718A4 (en) ANTIVIRAL TREATMENT USING THE B-OLIGOMER OF TOXIN COQUELUCHEUSE
EP0800396A4 (en) TREATMENT OF HYPERANDROGENIA CONDITIONS
MA24169A1 (en) TREATMENT OF ASTHMA USING TNFR-IG
EP0755255A4 (en) TREATMENT OF TOXOPLASMOSIS
EP0833641A4 (en) TREATMENT AND PREVENTION OF PROSTATIC DISEASES
FR2765214B1 (en) TREATMENT OF AGGREGATE WITH AN ANTI-DE-COATING LATEX
EP0866799A4 (en) APOLIPOPROTEIN E2 AND TREATMENT OF ALZHEIMER'S DISEASE
EP0981545A4 (en) TREATMENT OF OSTEOPOROSIS
PL322002A1 (en) Variants of human dnase i
FR2709964B1 (en) Antiviral pharmaceutical compositions proposed in the treatment of AIDS and Herpes.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000627

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/17 A, 7A 61K 38/28 B, 7A 61K 38/39 B, 7A 61K 38/26 B, 7A 61K 38/21 B, 7A 61K 38/21 J, 7A 61K 38:26 J, 7A 61K 38:28 J, 7A 61K 38:39 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000915